Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Lymphoma 3Leukemia 2Subcutaneous panniculitis-like T-cell lymphoma 1Neoplasms 1Myelodysplastic Syndromes 1Multiple Myeloma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell 1Lymphoma, Extranodal NK-T-Cell 1

Interventions

Cyclophosphamide 172fludarabine phosphate 132Tacrolimus 100Mycophenolic Acid 92fludarabine 90Busulfan 88Whole-Body Irradiation 83Peripheral Blood Stem Cell Transplantation 77Antilymphocyte Serum 71Melphalan 69Filgrastim 63Cyclosporine 62Methotrexate 54Radiotherapy 40Thiotepa 39Cord Blood Stem Cell Transplantation 35Granulocyte Colony-Stimulating Factor 34Stem Cell Transplantation 32thymoglobulin 29Sirolimus 27Methylprednisolone 26Rituximab 24Cytarabine 23Clofarabine 23Etoposide 22Alemtuzumab 20Azacitidine 17Specimen Handling 14Cyclosporins 13sargramostim 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Myelodysplastic Syndromes × siplizumab × Lymphoid × Clear all
NCT00113646 2018-03-16

Non-Myeloablative HLA-Mismatched Ex-Vivo T-cell Depleted Stem Cell Transplantation for Hematologic Malignancies

Massachusetts General Hospital

Phase 2 Terminated
14 enrolled
LymphoidMyeloidOther hematologic neoplasmPlasma cell

Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡